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Purpose: To evaluate the long-term outcomes of two-step versus single application 
of mitomycin-C (MMC) during photorefractive keratectomy (PRK) for high myopia.
Methods: This randomized clinical trial included consecutive patients with high 
myopia (exceeding 7 D). Patients underwent PRK and were randomized to two 
methods of MMC 0.02% application as follows: in the single application group, MMC 
was applied for 45 seconds followed by irrigation; in the two-step group MMC was 
used identically followed by repeat application for another 15 seconds and corneal 
surface irrigation. Visual acuity, refractive error, pachymetry, topography, corneal haze 
and complications were compared between the two groups 18 months after surgery.
Results: One hundred and forty patients (70 subjects in either study arm) underwent 
PRK according to the study protocol. Mean spherical equivalent refractive error was 
significantly reduced from baseline to -1.16±0.39 D in the single application group 
and to -1.07±0.39 D in the two-step group. Sixteen (11.5%) versus 8 (5.7%) eyes lost 
one or more line(s) of best corrected visual acuity in the single application group as 
compared to the two-step group (P=0.05). Corneal haze was observed in 18 (12.9%) and 
8 (5.7%) eyes in the single application versus two-step group, respectively (P=0.04). 
Grade 3 corneal haze was not observed in the two-step group but occurred in five 
eyes (3.6%) in the single application group (P=0.03). No eyes developed corneal 
ectasia during the follow-up period.
Conclusion: Two-step intraoperative application of MMC 0.02% in highly myopic 
eyes undergoing PRK can reduce the frequency and severity of haze formation.
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INTRODUCTION
Excimer laser photorefractive keratectomy (PRK) 
is a popular surgical procedure for correction 
of refractive errors.1-6 However, due to its side 
effects, i.e. slow visual recovery, discomfort 
in the early postoperative period and corneal 
haze, laser in situ keratomileusis (LASIK) 
remains an attractive alternative.7 Patients with 
myopia exceeding 5 diopters (D) and corneal 
thickness less than 500 µm are not suitable 
candidates for LASIK or conventional PRK 
due to inadequate corneal thickness and the 
risk of haze formation.8-11 In these eyes, LASIK 
may induce structural instability, irregular 
astigmatism, loss of best-corrected visual acuity Two-step vs Single MMC Application in PRK; Fazel et al
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(BCVA) and iatrogenic keratoconus.12
In highly myopic eyes unsuitable for 
laser ablation, phakic intraocular lens (PIOL) 
implantation may be a reasonable alternative. 
Highly myopic eyes may be treated by PRK if 
wound healing reactions such as haze formation 
could be effectively suppressed. PRK is an 
easy and non-invasive procedure as compared 
to PIOL implantation and avoids potential 
complications associated with intraocular 
surgery such as endophthalmitis. With very high 
amounts of myopia, PIOL implantation may be 
superior to PRK because of the considerable risk 
of haze formation.13,14 
Corneal haze formation after PRK is induced 
by activation and proliferation of keratocytes. 
Collagen produced by activated keratocytes 
is much less organized than normal stromal 
collagen and shows matrix-free areas and fibers 
with irregular stereospatial relationship.15-20 
Small case series have suggested that topical 
application of anti-proliferative agents such 
as mitomycin-C (MMC) can modulate haze 
formation and treat established haze.21-25 It has 
also been demonstrated that MMC application 
prevents corneal haze formation following PRK 
in moderate to high myopia.18-21,26-29
This study was designed to compare 
BCVA and corneal status 18 months after PRK 
employing two different methods of MMC 
0.02% application, and to investigate long-term 
refractive and mechanical stability, and late-
onset sequelae such as postoperative corneal 
haze.
METHODS
This randomized clinical trial consecutively 
enrolled patients with high myopia (greater than 
-7 D). All patients underwent PRK with MMC 
application at Feiz Hospital, Isfahan, Iran. All 
subjects attended lectures about the procedure, 
were counselled before randomization and 
provided informed consent for the procedure. 
One skilled surgeon with extensive experience 
with PRK operated all eligible patients in group 
A (single application) and group B (two-step 
application) of MMC. All patients underwent a 
detailed ocular examination including subjective 
and cycloplegic refraction, keratometry, corneal 
pachymetry, tonometry and dilated fundus 
examination.
Candidates 20 to 50 years of age, with stable 
refractive error for at least 2 years, cycloplegic 
refractive error exceeding -7 D, spherical 
equivalent refraction of -7.00 to -10.00 D, regular 
astigmatism, BCVA of 0.2 logMAR or better, 
corneal thickness of 500 to 700 µm, keratometry 
values of 43 to 47 diopters and normal endothelial 
cell counts were included. For being eligible for 
PRK, residual corneal thickness (excluding the 
epithelium) was required to be greater than 350 
µm. Patients with a history of ocular diseases or 
severe ocular trauma, previous keratorefractive 
procedures, contact lens wear during the past 
2 months, wound healing abnormalities (e.g. 
keloids), systemic disorders (diabetes mellitus, 
systemic lupus erythematosus or other connective 
tissue disorders), anterior or posterior uveitis, 
ectatic disorders such as keratoconus, corneal 
dystrophies or degenerations, glaucoma, retinal 
diseases, and lens opacities were excluded.
Operative Procedure
All patients received topical anesthesia without 
systemic sedation. Using an 8 mm ring, ethanol 
16% was applied in a marker well for 20 seconds. 
The epithelium was then removed mechanically 
using a sponge. Conventional ablation was 
performed using the Nidek EC 5000 excimer 
laser machine with a central optical zone of 6 
mm and transition zone of 7.5 mm. MMC 0.02% 
(0.2 mg/ml diluted in balanced salt solution) 
was applied immediately after laser ablation as 
follows: in the single application group, MMC 
was applied over the ablated stroma using a 
saturated sponge for 45 seconds. The corneal 
surface and the entire conjunctiva were then 
irrigated with 20-40 ml of cold normal saline 
solution. In the two-step group, MMC was 
applied for 45 seconds followed by irrigation 
as mentioned above. Thereafter, MMC was 
reapplied for another 15 seconds using the same 
concentration and in a similar fashion followed 
by corneal surface irrigation. At the end of the 
procedure, a bandage contact lens was applied 
which was removed after one week.Two-step vs Single MMC Application in PRK; Fazel et al
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Postoperatively, patients were examined 1 
and 3 days, 1 and 4 weeks, and 3, 6, 12 and 18 
months after PRK. All subjects were instructed to 
take an oral analgesic (diclofenac sodium) every 
8 hours, betamethasone eye drops every 4 hours 
for 2 weeks, and chloramphenicol eye drops 
every 6 hours for one week. During weeks 3 and 
4, all patients were treated with betamethasone 
eye drops and artificial tears every 6 hours which 
were tapered to every 8 and 12 hours during 
the second and third postoperative months 
respectively and discontinued thereafter. All 
patients were instructed to wear sunglasses in 
direct sunlight for 3 months. During the first 
postoperative week, all patients underwent slit 
lamp biomicroscopy and the size of epithelial 
defect was measured using its ruler to identify 
time for complete re-epithelialization. At each 
visit, refraction and slit lamp examination were 
performed. At final follow-up (18 months), 
pachymetry and topography (Zeiss-Humphrey, 
Jena, Germany) were also obtained. We employed 
Hanna’s grading scale from 0 (no haze) to +4 
(dense white corneal haze) to categorize corneal 
haze.17 
Data analysis was performed using the SPSS 
software version 16. Refractive errors in eyes 
which required cylindrical corrections were 
converted to spherical equivalents (SE). Data of 
right and left eyes were analyzed independently 
as surgery was conducted independently for 
fellow eyes. The statistical level of significance 
was set at 0.05.
RESULTS
Overall, 280 eyes of 140 patients including 70 
subjects in either study arm were operated. 
The single application group consisted of 46 
female (65.5%) and 24 male (34.3%) subjects 
and the two-step group included 50 female 
(71.3%) and 20 male (28.6%) patients (P=0.031). 
Mean patient age at the time of allocation was 
26.3±2.6 (range, 20-46) years. Mean age was 
25±3.7 years in the single application group and 
25±4.2 years in the two-step group (P=0.070). 
Mean SE refractive error was -8.40±0.80 D 
in the single application versus -8.51±0.92 
D in the two-step groups, respectively. No 
significant difference was found between the 
two groups in terms of preoperative manifest 
refraction and postoperative refractive error. 
SE was significantly (P=0.001) reduced to 
-1.16±0.39 D and -1.07±0.39 D in the single 
application and two-step groups, respectively. 
Table 1 summarizes changes in refractive 
parameters; mean change in SE are shown   
in Table 2. 
BCVA did not change or was improved 
in 124 (88.5%) of eyes in the single application 
group and in 132 (94.3%) of eyes in the two-step 
group (P=0.05) (Table 3). 
After 18 months, corneal haze formation 
occurred in 18 (12.9%) of eyes in the single 
application group versus 8 (5.7%) of eyes in 
the two-step group (P=0.04). Grade 3 corneal 
haze was not seen in any eye in the two-step 
group but occurred in five eyes (3.6%) in the 
single application group (Table 4 and Fig. 1). 
Haze formation was noted in all patients with 
loss of BCVA.
There were no cases of progressive 
corneal ectasia up to 18 months follow-up. No 
complications such as eccentric ablation, delayed 
Single application Two-step 
P-value*
Mean ± SD Min, Max Mean ± SD Min, Max
Pre-op -8.4 ± 0.8 -7.25, -10 -8.57 ± 0.92 -7.2, -10.75 0.08
Post-op -1.16 ± 0.39 -0.50, -2.00 -1.07 ± 0.39 -0.25, -1.75 0.06
Table 2. Changes in spherical equivalent refractive error in either study group
SD, standard deviation
*Independent t-test
Parameter
Mean ± SD (range)
Preoperative Postoperative
CIM 1.09 ± 0.74
(0.46 to -5.55)
1.93 ± 10.14
(0.18 to -1.16)
SF 0.347 ± 0.182
(-0.66 to 0.62)
-0.951 ± 0.622
(-1.23 to 1.33)
Pachymetry (µm) 532 ± 37
(481 to 643)
432 ± 38
(390 to 553)
Table 1. Refractive data for 280 eyes of 140 patients
SD, standard deviation; CIM, corneal irregularity measure; SF, 
shape factorTwo-step vs Single MMC Application in PRK; Fazel et al
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re-epithelialization, persistent epithelial defect, 
or microbial keratitis were observed.
DISCUSSION 
Treatment of high myopia using PRK remains 
a challenge. The higher rate of haze formation 
together with regression of refractive correction 
has decreased interest in PRK, as compared 
to LASIK, for treatment of high ametropias, 
including high myopia.7,18,26,30 However, LASIK 
may not be feasible in eyes with insufficient 
residual corneal stromal thickness. One solution 
is application of smaller ablation zones; this may 
lead to impaired night vision, halos, blurred 
vision, and ghost images.
Recently, the role of PRK has been 
reappraised because of corneal instability and 
poor visual function frequently reported in 
highly myopic patients following LASIK.7,31 
Nevertheless, haze formation continues to be 
the major drawback to PRK for high mypoia.32 
If the safety and predictability of PRK with 
MMC can be verified, larger ablation depths 
may be employed and the above mentioned 
complications will be avoided, making surface 
ablation a safe alternative for correction of high 
refractive errors.33
MMC is an antimetabolite used in 
ophthalmology for cases of corneal and 
conjunctival intraepithelial neoplasms, ocular 
pemphigoid and during surgical treatment 
of glaucoma and pterygium. It employs its 
cytotoxic effects through inhibition of DNA 
synthesis. The rationale for its use in PRK is 
based on prevention of keratocyte proliferation 
and deposition of irregularly generated material 
leading to scar formation.34,35 The effect of 
MMC 0.02% in preventing haze formation has 
previously been shown by Talamo et al36 and 
Xu et al37 in experimental models. It has also 
been reported that the application of MMC can 
decrease pre-existing haze following PRK and 
radial keratectomy.21-23 Carones et al18 reported 
acceptable refractive and visual outcomes over a 
6-month period following PRK with MMC 0.02% 
for moderate and high myopia.
Kymionis et al38 evaluated aqueous humor 
concentrations of MMC following PRK in 24 
eyes of 12 male rabbits in 4 groups. Eyes in 
groups 1 and 2 underwent PRK to correct 5 D 
of myopia in a 6-mm optical zone followed by 
MMC 0.02% application on the ablated corneal 
stroma for 60 and 120 seconds, respectively. Eyes 
in groups 3 and 4 underwent PRK to correct   
10 D of myopia in a 6-mm optical zone followed 
by MMC 0.02% application for 60 and 120 
seconds, respectively. Mean aqueous humor 
concentrations of MMC were 0.23±0.03, 0.39±0.05, 
0.28±0.04 and 0.52±0.16 µg/mL in groups 1, 2, 
 Two-step  Single application
Corneal haze scale
% N % N
3.94 132 1.87 122 0
3.4 6 5 7 +1
4.1 2 3.4 6 +2
0 0 6.3 5 +3
100 140 100 140 Total
Table 4. Corneal haze formation at final visit
Lines lost
Unchanged
Lines gained
≤2 1 1 ≤2
Single application 5 (3.6%) 11 (7.2%) 112 (80%) 10 (7.1%) 2 (1.4%)
Two-step 2 (1.4%) 6 (4.3%) 114 (81.4%) 12 (8.6%) 6 (4.3%)
Table 3. Changes in best-corrected visual acuity in the study groups
t-test, P=0.05
Figure 1. Percentage of haze formation in the study 
groupsTwo-step vs Single MMC Application in PRK; Fazel et al
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3, and 4, respectively. The investigators showed 
that both duration of exposure (P<0.001) and 
ablation depth (P=0.019) were significantly 
correlated with MMC concentration in the 
aqueous humor.
Haze formation and regression after PRK 
are more common in people of Middle Eastern 
origin.39 Other important predictors of haze 
formation are the amount of correction and 
the size of ablation zone. A 6 mm optical zone 
and a minimum of 7 D of correction, practically 
limited our study to patients who were at a 
high risk of haze formation following PRK. 
Maximum ablation depth in our patients was 
160 µm, minimal residual corneal thickness 
was 400µm and no patient developed corneal 
ectasia after 18 months. It seems that residual 
corneal thickness of 400 µm after PRK is safe in 
terms of preventing iatrogenic ectasia, however 
further studies are warranted to approve this 
conclusion.
The current study was designed to evaluate 
the efficacy and long-term stability of PRK with 
single (45 seconds) versus two-step (45 seconds 
followed by 15 seconds) application of MMC 
0.02% on the ablated stromal bed in highly 
myopic eyes. We sought to determine whether 
a small increase in duration of MMC application 
can decrease corneal haze formation following 
PRK for high myopia. To decrease penetration 
of MMC into the corneal stroma and anterior 
chamber, we irrigated the corneal surface after 
MMC application. 
Refractive and visual outcomes in our series 
were better than studies on LASIK for correcting 
the same amount of myopia.40,41 Moreover, 
outcomes of two-step application of MMC 
were better than those of a single application 
(routine practice). We found no similar study 
to compare our results with. Out of 83 articles 
investigating MMC administration for PRK in 
the PubMed database, only a few compared 
different durations of MMC application. 
Wallau et al42 reported the one-year results 
of PRK with one minute application of MMC 
for customized correction of myopia. Clinically 
significant haze was not found following surface 
ablation; 74% of MMC-PRK and 43% of LASIK 
eyes gained one or more lines of BCVA 12 months 
postoperatively. Thornton et al43 compared the 
safety and efficacy of low concentration MMC 
(0.002%) with that of standard concentration 
(0.02%) in eyes undergoing PRK for myopia. 
The duration of exposure varied from 30 seconds 
to 2 minutes in both groups. With multivariate 
analysis, significantly less haze formation was 
noted at all postoperative time points with the 
standard dose in eyes with high myopia and 
greater ablation depths. In contrast, haze levels 
were similar with both MMC concentrations in 
eyes with moderate myopia and lower ablation 
depths. In the subset of contralateral eyes which 
randomly received low dose MMC (0.002%) for 
30 seconds or 2 minutes, no significant difference 
was found in terms of haze formation.
Considering the fact that haze influences 
BCVA, we independently analyzed BCVA in our 
study. With a single application of MMC, 16 
eyes (11.5%) lost one or more line(s) of BCVA 
after surgery as compared to 8 eyes (5.7%) in 
the two-step MMC group. Major side effects 
(corneal edema, melting or perforation) or minor 
complications (corneal sensitivity or tear film 
problems) associated with the use of MMC were 
not observed in any of the study groups. None 
of the eyes in the two-step group had significant 
grades of corneal haze or degenerative reactions 
after surgery. Many studies have highlighted the 
toxicity of MMC on the corneal endothelium, 
however our study was not designed to address 
this issue. Considering the corneal penetration 
of MMC and susceptibility of its endothelium, 
additional studies are needed to determine the 
long-term impact of MMC use during PRK on 
the corneal endothelium.44 Another important 
finding in our study was the absence of corneal 
ectasia despite increased attempted corrections. 
Corneal ectasia following refractive surgery is a 
long-term complication which may appear up 
to a decade after initial treatment, therefore, 
longer follow-up is necessary to draw a definite 
conclusion.
Refractive surgery procedures such as PRK 
which involve mechanical removal of the corneal 
epithelial barrier, excimer laser stromal ablation, 
and subsequent MMC treatment, expose the 
cornea to substantial levels of MMC. Length 
of exposure and MMC concentration in the Two-step vs Single MMC Application in PRK; Fazel et al
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endothelium and aqueous humor are directly 
related to the amount of MMC applied to 
the anterior surface. Based on established 
mechanisms of MMC action, in vitro and animal 
studies, and reports of intraocular penetration 
after MMC in non-PRK treatments, MMC has 
the potential to damage cellular DNA.45,46 
However, corneal irrigation between stepwise 
MMC application can theoretically reduce the 
risk of these complications.
In conclusion, longer duration of MMC 
administration, i.e. 45 seconds followed by an 
additional 15 seconds, in PRK for myopia higher 
than -7 D seems to be safe and may reduce 
corneal haze formation after surgery. 
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